This Is Why ASML Is a No-Brainer Buy Before July 15 Earnings

Photo of Joel South
By Joel South Published

Quick Read

  • ASML's monopoly on EUV lithography and a July 15 Q2 earnings catalyst could push shares 11% higher to $2,023 from $1,831.

  • Unlike AMAT and LRCX, ASML sells the only EUV lithography systems on earth, where CEO Fouquet says supply cannot meet demand through 2026.

  • A EUR 12 billion buyback through 2028 and a 17% dividend hike reinforce confidence in ASML's $13 billion annual free cash flow.

  • This lithium producer surpassed a $1B private valuation, joining some of America's most powerful startups. Now you can invest in EnergyX alongside global giants like General Motors, but only through July 16. (sponsor)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
This Is Why ASML Is a No-Brainer Buy Before July 15 Earnings

© Intel

Own ASML Holding (NASDAQ:ASML | ASML Price Prediction) before the opening bell on July 15 when the company reports Q2 results and almost certainly reiterates a raised full-year outlook the market is still underpricing. The thesis rests on the fact that ASML is the only company on earth that sells EUV lithography, at a moment when its own CFO says “2026 is panning out very nicely” and management just widened FY guidance upward.

ASML price target

The Setup Into July 15

ASML traded around $1,804.25 last Friday, sitting 8% below its 52-week high of $1,999.96, with the 24/7 Wall St. base case pointing to $2,022.82 and a 0.9 (High) confidence score. The shares are already up 124.48% over the past year and 65.91% year to date, and the tape shifted violently in the buyer’s favor Thursday, with the stock rallying 3.5% intraday ahead of the earnings report.

Three Reasons the Decision Is Easy

1. The Q2 catalyst is loaded: Management already raised FY2026 revenue guidance to EUR 36 billion to EUR 40 billion on the Q1 call, with CFO Roger Dassen calling it “a very strong year”. Q1 2026 already delivered EPS of $8.43 and revenue of $10.34 billion, with gross margin printing at 53.0%, the high end of guidance. Q2 guidance sits at EUR 8.4 billion to EUR 9.0 billion.

2. The demand picture is structural: CEO Christophe Fouquet told investors that “supply will not meet the demand for the foreseeable future” and that memory customers are “sold out for 2026”. The 2025 backlog closed at $45.06 billion against Q4 net bookings of $15.28 billion.

3. Capital return is accelerating: ASML activated a EUR 12 billion buyback in January 2026 running through 2028 and lifted the FY2025 dividend 17% to EUR 7.50 per share. FY2025 free cash flow hit $12.81 billion.

ASML earnings explorer

Why Not Applied Materials or Lam Research?

Because Applied Materials (NASDAQ:AMAT) and Lam Research (NASDAQ:LRCX) do not sell lithography and cannot. ASML is the sole global supplier of EUV lithography systems for every sub-7nm node in production. That monopoly showed up in the numbers: EUV lithography systems revenue grew 39% to $13.47 billion in FY2025 while ASML’s non-lithography peers fought over deposition and etch dollars in a commoditizing pricing environment. AMAT and LRCX are fine businesses. Neither will ship a single High NA EXE:5200B tool this decade.

The setup points to July 15 as the next major catalyst.

Contact [email protected] for any questions or corrections.

Photo of Joel South
About the Author Joel South →

Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.

He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.

Continue Reading

Top Gaining Stocks

META Vol: 40,760,422
KMX Vol: 2,288,021
WY Vol: 6,523,553
SBAC Vol: 1,443,801
NVDA Vol: 148,249,982

Top Losing Stocks

MRNA Vol: 9,176,778
CTRA Vol: 73,319,495
CRWD Vol: 9,269,567
DDOG Vol: 5,135,556
EPAM Vol: 1,164,561